Novavax NVAX Enterprise value

Enterprise value at other companies

ModernaMRNA

$27.3B+177%

Vaxcyte, Inc.PCVX

$8.22B+78.6%

Merck & Co.MRK

$367.21B+59.3%

ALN

Alnylam PharmaceuticalsALNY

$38.74B-6.7%

Roivant SciencesROIV

$25.49B+225%

Gilead SciencesGILD

$179.93B+17.5%

FAQ

What is Novavax's enterprise value?

Novavax (NVAX) reported enterprise value of $1.65B in Q2 2026.

How has Novavax's enterprise value changed year-over-year?

Novavax's enterprise value increased by 93.5% year-over-year, from $855.37M to $1.65B.

What is the long-term trend for Novavax's enterprise value?

Over 5 years (2020 to 2025), Novavax's enterprise value has grown at a -32.7% compound annual growth rate (CAGR), from $8.18B to $1.13B.

What does enterprise value mean?

Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.